Interpace Biosciences Guides Q3 Revenue Up 11-14% Sequentially to $10.1M-$10.4M
IDXG sits 43% above its 52-week low of $3.85 on light trading volume (0.1× avg).
Summary
Interpace Biosciences pre-announced Q3 2026 revenue of $10.1M to $10.4M, up 11-14% from Q2's $9.1M and 15-18% from $8.8M a year ago. The growth is driven by its core thyroid testing business, which grew 9% in Q2 and returned the company to profitability. This preliminary range suggests accelerating momentum and supports the recent Nasdaq uplisting effort following the 1-for-5 reverse split in August. Full Q3 results are expected at a later date, with actual figures subject to closing adjustments.
At the time of this announcement, IDXG was trading at $5.52 on OTC in the Life Sciences sector, with a market capitalization of approximately $32.6M. The 52-week trading range was $3.85 to $12.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.